This site is intended for healthcare professionals
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

EACCME® accredited eLearning

Read time: 60 mins
Last updated:16th Dec 2021
Published:16th Dec 2021

Take part in our interactive EACCME®-accredited eLearning module to explore molecular tests and targeted treatment options for RET-altered non-small cell lung cancer (NSCLC) and thyroid cancers.

  • Learn about the diagnostic techniques to detect RET alterations
  • Discover how RET inhibitors work
  • Review the evidence for RET inhibitor efficacy and safety
  • Find out how to interpret molecular tests for optimal treatment decisions

Take our eLearning module to learn all this and more.

Molecular diagnostics for RET inhibition: from sampling through to results

This module is designed for oncologists, pulmonologists, endocrinologists, specialist nurses, GPs, and all healthcare professionals involved in treating and managing patients with suspected RET-altered NSCLC or thyroid cancer. 

Enrol

Course overview

How much do you already know about RET-altered NSCLC and thyroid cancers, and how to detect these alterations and interpret the results? Take this interactive learning module to learn about RET inhibition, molecular diagnostic tests, sample requirements, and how to interpret test results to inform treatment. You will hear from a clinical expert, and have the opportunity to test your knowledge in our interactive quiz and patient case study.

System Requirements

Faculty

Professor Fernando Lopez-Rios.jpgProfessor Fernando Lopez-Rios was involved in reviewing the content contained in the module. Professor Fernando Lopez-Rios recently joined the Department of Pathology at ‘12 de Octubre’ University Hospital (Madrid). He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University, respectively, and completed his residency in Pathology at ‘12 de Octubre’ University Hospital (Madrid). Professor Lopez-Rios has also been the Director of Pathology & Laboratory of Therapeutic Targets at ‘HM Hospitales’ for 15 years, and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.

Assessment Questions Assessment and certificate access  
Section Content outline Time (60 mins total)
1 Introduction to RET-altered NSCLC and thyroid cancers, and RET inhibitor indication and mechanism of action 20 mins
2 Molecular diagnostics 15 mins
3 Molecular sampling 10 mins
4 Interpreting results 10 mins
5 Patient case study 5 mins

Further information

You will be asked survey questions before and after the module, which are ungraded. There are graded knowledge questions at the end of each section, as well as one patient case study, which is also graded. To pass the course and receive your CME credit and certificate, you must achieve a score of 70% or above.

At the end of the module, you will also be asked to complete a short survey, giving you the chance to provide feedback on your experience. On completion of this module, participants will understand:

  • prevalence of RET alterations in NSCLC and thyroid cancers
  • RET inhibitor mechanism of action and approved indications for treatment
  • evidence of the effectiveness of approved RET inhibitors to treat RET-altered NSCLC and thyroid cancers
  • molecular testing techniques to detect RET alterations, and sampling requirements
  • how to interpret molecular test results to inform treatment decisions

Molecular diagnostics for RET inhibition: from sampling through to results

This module is designed for oncologists, pulmonologists, endocrinologists, specialist nurses, GPs, and all healthcare professionals involved in treating and managing patients with suspected RET-altered NSCLC or thyroid cancer. 

Enrol

Welcome: